



# SITUATION REPORT

## **Nigeria Centre For Disease Control (NCDC)**

NCDC.GOV.NG

PLOT 800 EBITU UKIWE STREET, JABI ABUJA, NIGERIA TOLL FREE CALL: 6232 E:info@ncdc.gov.ng

@NCDCgov ♠ ❤️ 💆 🌀

TITLE: UPDATE ON MPOX (MPX) IN NIGERIA

SERIAL NUMBER: 49

EPI-WEEK: 49

DATE: December 10, 2023

#### **Table 1 – Key Indicators**

Reporting Year	Reporting week	Suspected cases	Confirmed cases	Deaths (Confirmed cases)	Case Fatality Ratio (CFR)	States Affected (Confirmed cases)	LGAs Affected (Confirmed cases)
2023 Current	Week 49	23	0	0	0.0	0	0
2023 Cumulative	Week 49	1154	95	2	2.4	24 +FCT	62
2022 Cumulative	Week 49	1987	743	7	1.0	34 + FCT	233

## **Highlights**

- In week 49, the number of new suspected cases is 23, compared with 20 cases reported in week 48, 2023. These were reported from eight (8) States Ogun (9), Katsina (4), Ekiti (3), Delta (2), Lagos (2), Nasarawa (1), Osun (1) and Akwa Ibom (1) across 14 Local Government Areas.
- Since week 1 of 2023, twenty-four (24) States and FCT have recorded at least one confirmed Mpox case across sixty-two (62) Local Government Areas. In 2023, the States with the highest burden are Lagos (28.6%), Ogun (18.7%), Abia (6.6%), Imo and (6.0%) and Edo (6.0%), contributing 64.8% of confirmed cases.
- The number of confirmed cases is zero (0) in week 49, 2023, compared with four (4) confirmed case reported in week 48, 2023.
- No death was recorded in week 49, with a CFR of 0.0% same as CFR of 0.0% that was reported in week 48, 2023.
- Overall, since the re-emergence of Mpox in September 2017, 3743 suspected cases have been reported from 36 States and FCT in the country. Of these 3743 suspected cases, 1083 (29.1%) were confirmed (with males predominantly affected) from 34 States and FCT. seventeen (17) deaths have been recorded since the re-emergence in 2017.
- The National Mpox multi-partner, multi-sectoral Technical Working Group (TWG) continues to coordinate the response activities at all levels.




















Figure 1: Epidemic curve of suspected and confirmed Mpox cases January 2023 till date.




Figure 2: Age and sex distribution of Nigeria confirmed monkeypox cases from January 2023 till date.






















**Figure 3:** Map of Nigeria showing States with suspected and confirmed Mpox Cases from January 2023 till date.




Figure 4: Nigeria confirmed Mpox cases by the year of incidence- September 2017 to 10<sup>th</sup> December 2023.





















**Table 1:** Summary statistics for annual Nigeria Mpox cases by reporting year, September  $2017 - 10^{th}$  December 2023

Reporting year	Suspected cases	Confirmed cases	Deaths (Confirmed cases)	Case Fatality Ratio (CFR)	States Affected (Confirmed cases)	LGAs Affected (Confirmed cases)
2023	1154	95	2	2.1	24 +FCT	62
2022	2123	762	7	0.9	34 + FCT	238
2021	98	34	0	0.0	8 + FCT	25
2020	35	8	0	0.0	5	7
2019	65	47	1	2.1	11	26
2018	116	49	1	2.0	13	25
2017	198	88	6	6.8	14 + FCT	33

**Table 2:** Age distribution of cumulative number of confirmed Mpox cases September  $2017 - 10^{th}$  December 2023

Age Group	2017	2018	2019	2020	2021	2022	2023	Total
0-10 Years	7	5	1	0	1	125	19	158
11-20 Years	12	4	1	0	4	123	8	152
21-30 Years	34	13	13	4	10	187	24	285
31- 40 Years	26	17	22	4	13	205	21	308
41-50 Years	9	10	9	0	5	89	17	139
> 50 Years	0	0	1	0	1	33	6	41
Total	88	49	47	8	34	762	95	1083

**Table 3:** Nigeria confirmed Mpox cases by State, September 2017 – 10<sup>th</sup> December 2023

S/N	State	2017	2018	2019	2020	2021	2022	2023	Total
1	Lagos	4	1	15	4	6	188	27	245
2	Rivers	25	14	7	1	5	37	4	93
3	Bayelsa	19	11	7	0	6	45	2	90
4	Abia	1	2	0	0	0	58	6	67
5	Delta	3	6	10	1	9	31	1	61
6	Imo	5	2	1	0	0	45	5	58
7	Ogun	0	0	0	0	1	40	17	58
8	Ondo	0	0	0	0	0	40	2	42
9	Edo	4	1	1	0	4	27	4	41
10	FCT	5	0	0	0	1	25	4	35
11	Anambra	0	1	1	0	0	25	0	27
12	Cross River	9	3	1	0	1	12	1	27
13	Kwara	0	0	0	0	0	21	0	21
14	Plateau	0	2	0	1	0	16	0	19
15	Akwa Ibom	6	0	1	0	0	12	4	23
16	Nasarawa	1	1	0	0	0	17	1	20
17	Adamawa	0	0	0	0	0	16	0	16
18	Oyo	1	3	2	0	0	10	1	17
19	Kaduna	0	0	0	0	0	15	2	17
20	Ebonyi	0	0	0	1	0	12	1	14
21	Benue	2	0	0	0	0	10	0	12
22	Borno	0	0	0	0	0	11	2	13
23	Enugu	1	2	1	0	0	4	3	11
24	Katsina	0	0	0	0	0	8	1	9
25	Taraba	0	0	0	0	0	7	0	7

...PROTECTING THE HEALTH OF NIGERIANS



















30	Grand Total	88	<b>49</b>	<b>47</b>	8	34	<b>762</b>	95	1083
36	Jigawa	0	0	0	0	0	0	1	1
35	Yobe	0	0	0	0	0	1	0	1
34	Zamfara	0	0	0	0	0	1	0	1
33	Bauchi	0	0	0	0	0	1	0	1
32	Kebbi	0	0	0	0	0	2	1	3
31	Niger	0	0	0	0	1	1	1	3
30	Ekiti	2	0	0	0	0	1	1	4
29	Osun	0	0	0	0	0	5	1	6
28	Kogi	0	0	0	0	0	5	2	7
27	Gombe	0	0	0	0	0	6	0	6
26	Kano	0	0	0	0	0	7	0	7

#### **Response activities**

Pillar	Activities to date	Next steps
Coordination	<ul> <li>Facilitating the smooth running of the weekly Mpox technical working group meetings</li> <li>Providing offsite subnational support to resolve issues in reporting States</li> </ul>	Follow-up implementation of the approved Incident Action plan activities in collaboration with other pillars
Surveillance	<ul> <li>Twenty three (23) suspected Mpox cases were reported from 8 States</li> <li>No confirmed cases were recorded</li> </ul>	Continue to support all State     Surveillance teams to ensure on     SORMAS
Laboratory	The sample positivity rate for Mpox is 0% and 61% for Varicella-Zoster Virus (VZV)	Continue to support effective sample management and transportation to the NRL from health facilities across the country

#### Notes on this report.

#### Data Source

Information for this disease was case-based data retrieved from the National Mpox Emergency Operations Centre.

#### **Case definitions**

#### Suspected case

• An acute illness with fever >38.3°C, intense headache, lymphadenopathy, back pain, myalgia, and intense asthenia followed one to three days later by a progressively developing rash often beginning on the face (most dense) and then spreading elsewhere on the body, including soles of feet and palms of the hand.

#### Probable case

• A case that meets the clinical case definition is not laboratory-confirmed but has an epidemiological link to a confirmed case.

### Confirmed case.

• A clinically compatible case that is laboratory confirmed

#### Contact



















 Any person who has been in direct or indirect contact with a confirmed case since the onset of symptoms, i.e., contact with skin lesions, oral secretions, urine, faeces, vomitus, blood, sexual contact, sharing a common space (anyone who has been in proximity with or without physical contact with a confirmed case)

#### **Calculations**

• Case Fatality Rate (CFR) for this disease is reported for confirmed cases only.



















